A Singular Focus on Advancing Science and Medicine

We are taking sequencing further to bring you fast, powerful and flexible tools for research and precision medicine. Our aim is to empower scientists to answer their most pressing questions, allowing them to forge a path of discovery without limits.

Join The Team
About Us

Our Story

Pin + Pencil

Where We Started

Genomic technologies developed over the last two decades have greatly improved our understanding of biology. Yet, the transformative potential of genomics is just starting to be realized.

Based on real-world feedback from scientists and clinicians on the limitations of today’s sequencing tools, Drew Spaventa, Eli Glezer, and David Barker created Singular Genomics to build better products with greater impact.

Pin

Where We Are Today

We have assembled a dynamic team focused on producing advanced technologies that will improve the accessibility and efficiency of genomic sequencing.

Through the G4, our first commercial product, we have delivered a novel, highly versatile benchtop sequencer designed to produce fast and accurate genetic sequencing results.

Pin + Plus

Where We Are Heading

Looking ahead, the team at Singular Genomics is committed to unlocking the potential of our core technologies to reshape the future of genomic sequencing.

We’re actively developing the PX, the world’s first integrated single cell sequencing and spatial profiling platform.

Executive Team

Drew Spaventa

Chief Executive Officer & Founder

Eli Glezer

Chief Scientific Officer & Founder

Sam Ropp

Chief Commercial Officer

Dalen Meeter

Chief Financial Officer

Laure Moller

VP, Customer Solutions & Support 

Jorge Velarde

SVP Corporate Development & Strategy

Vincent Brancaccio

Head of Human Resources

Board of Directors

Drew Spaventa

Drew Spaventa

Chairman & CEO

Mike Pellini

Board Member

David Barker

Board Member & Founder

Kim Kamdar

Board Member

Jason Ryan

Board Member

Elaine Mardis

Board Member

Marcia Eisenberg

Board Member

Scientific Advisory Board

Eli Glezer

CSO & Founder

David Barker

Board Member & Founder

Elaine Mardis

Board Member

David Ledbetter

David Ledbetter

Advisory Board Member

Daniel Shoemaker

Daniel Shoemaker

Advisory Board Member

Larry Fong

Larry Fong

Advisory Board Member

Laure Moller

Laure joined Singular Genomics with more than 18 years of experience in scientific customer support for the life science industry. Most recently, Laure was the Vice President of Scientific Support at Meso Scale Diagnostics where she advanced adoption of the entire product portfolio, including immunoassays, hardware, and software. Laure also managed the scientific support of international distribution partners.

Laure received a PhD in Biochemistry and a BS in Biochemistry and Microbiology from the University of Cape Town.

Laure-Sitting-About-2

Marcia Eisenberg

Since 2014, Dr. Eisenberg has served as Chief Scientific Officer of Labcorp Diagnostics and more recently was appointed as Labcorp’s Enterprise Chief Scientific Officer. She served in a variety of other roles at Labcorp and its affiliates starting in 1990. Dr. Eisenberg has extensive experience with forensic DNA testing, biotechnology, molecular genetics, and molecular oncology. She has helped lead the development and validation of well over a thousand clinical assays used for patient care during her more than 30-year tenure at Labcorp.

Dr. Eisenberg previously held roles on the National Institute of Environmental Health Sciences and the Federal Bureau of Investigation’s DNA Advisory Board, where she was later recognized for her contributions to the advancement of DNA technology. A molecular biologist by training, Dr. Eisenberg was a member of the team responsible for commercializing polymerase chain reaction (PCR) tests in the 1990s, making large-scale testing possible. Dr. Eisenberg has been recognized multiple times in her career including as a Healthcare Businesswomen’s Association Luminary in 2021, as one of Fierce Healthcare’s 2021 Women of Influence, and as one of the Fierce Healthcare’s Fiercest Women in Life Sciences in 2022.

Dr. Eisenberg received her B.S. degree in Biology and her B.A. degree in Psychology from the State University of New York at Albany, her M.S. degree in Molecular Biology from the State University of New York at Albany, and her Ph.D. in Molecular Biology from the University of Kentucky.

 

Dr_Marcia_Eisenberg_Headshot

Sam Ropp

Sam leads the commercial function at Singular Genomics. He brings nearly 20 years of commercial experience, including sales, marketing and business development, to his role of Chief Commercial Officer. Sam joined Singular from 10x Genomics, most recently serving as Senior Vice President of Global Sales, where he was responsible for leading all aspects of regional sales, marketing, support, and global sales operations. Previously, Sam held senior leadership roles at Becton, Dickinson and Company (BD), and brings expertise from tenures at Molecular Devices (Danaher Corporation) and Bio-Rad Laboratories. 

Sam received a Ph.D. in Biomedical Sciences and an M.S. in Anatomy and Physiology from Wright State University, and a B.S. in Biology and Kinesiology from Stephen F. Austin State University.

Sam Ropp Headshot

Daniel Shoemaker

Over the past 25 years, Daniel has helped build several highly successful organizations from startup to public companies.  He most recently served as the Chief Scientific Officer of Fate Therapeutics (2009 -2021) where he lead the innovation efforts to bring multiple iPSC derived cell therapies to the clinic.  Prior to Fate, Dr. Shoemaker was Chief Scientific Officer of ICx Biosystems (2003-2009), a biotechnology firm that developed advanced detection technologies for use in biodefense, cancer and prenatal diagnostics. From 1998 to 2003, Dr. Shoemaker was one of the founding scientists at Rosetta Inpharmatics which developed a novel microarray platform and suite of bioinformatics tools for analyzing large genomic data sets.  After being acquired by Merck, Daniel served as Senior Director of Genomics where he was responsible for target discovery.  Dr. Shoemaker received his Ph.D. in biochemistry from Stanford University and his B.S. in biochemistry from the University of California, Santa Barbara.

Daniel Shoemaker

David H. Ledbetter, Ph.D., FACMG, DABMGG

Dr. Ledbetter is board certified by the American Board of Medical Genetics and Genomics as a clinical genetics laboratory director and built large genetics diagnostics programs throughout his academic career at Baylor College of Medicine, the University of Chicago, and Emory University School of Medicine. He is internationally recognized for his research on the genetic basis of childhood neurodevelopmental disorders, having discovered the genetic cause of Prader-Willi syndrome (1981) and Miller-Dieker syndrome (1983) very early in his career. Since that time, he has made numerous contributions to the translation of new genomics technologies into clinically useful genetic tests for early diagnosis and intervention in autism and related disorders. Dr. Ledbetter served as Executive Vice President and Founding Chief Scientific Officer at Geisinger for 10 years (2010-2020), where he helped lead their MyCode biobank/genomics project – one of the largest in the world. His current research interest includes leveraging longitudinal electronic health information with large-scale DNA sequencing to determine the clinical utility and cost-effectiveness of precision medicine approaches in real-world health system settings.

Dr. Ledbetter currently serves as Chief Clinical & Research Officer at Unified Patient Network, Inc., a start-up company building a massive Precision Medicine database across multiple healthcare systems linking patient EHR and other clinical data sets to clinical whole genome sequence data.

He is a graduate of Tulane University and earned his Ph.D. at the University of Texas-Austin.

David Ledbetter

Larry Fong

Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program.  He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center.  He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and an NIH-funded research lab. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors. He has also been involved in multiple first-in-human clinical trials including trials of dendritic cell vaccines, ipilimumab and an adenosine receptor antagonist. Dr. Fong’s research examines the mechanisms that underlie clinical response and resistance to immunotherapies. This work includes tracking antigen-specific T cell responses in treated cancer patients and developing biomarkers that are associated with clinical outcomes. The Cancer Immunotherapy Program that he directs performs early phase and high risk clinical trials across different disease indications. This program also includes a translational laboratory that performs mechanistic studies on samples derived from patients undergoing treatment.  Throughout his career, Dr. Fong has received multiple awards including the NIH Outstanding Investigator Award.

Dr. Fong obtained his BA from Columbia and MD from Stanford.  He completed internal medicine training at University of Washington, and oncology fellowship and post-doctoral training at Stanford in 2002.  He then moved to UCSF as an assistant professor where he is now a distinguished professor. He is an elected member of Alpha Omega Alpha and the American Society for Clinical Investigation.  He has over 100 publications in journals including NEJM, Nature, Nature Medicine, Cell, Immunity, and Cancer Discovery. He has served on multiple NIH study sections, the NCI Steering Committees for Genitourinary Cancer (GUSC), the NCI Investigational Drugs (IDSC)-Immunotherapy Task Force, the Department of Defense Prostate Cancer Research Program (PCRP) Vision Setting Committee, and NCI Immuno-oncology Translation Network (IOTN) Steering Committee. He has also served on multiple journal editorial boards including the Journal of Clinical Oncology, Journal of Immunotherapy of Cancer, and Cancer Immunology Research. 

Dr. Fong cofounded several companies including FWB LLC (acquired by Streamlogic), Techbargains.com LLC (acquired by Exponential), and Keyhole Therapeutics. He has ongoing research collaborations with Abbvie, Amgen, Bavarian Nordic, Bristol Myer Squibb, Dendreon, Janssen, Merck, and Roche/Genentech. He sits on the steering committee of the Roche/Genentech imCORE network. He also has served on multiple scientific advisory boards including Alector (ALEC), Atreca (BCEL), Bioatla (BCAB), Bolt (BOLT), Ideaya (IDYA), Innovent (IVBXF) Nutcracker, RAPT (RAPT), Senti, Soteria, TeneoBio (acquired by Amgen), and Xyphos (acquired by Astellas).

Larry Fong

Elaine Mardis

Dr. Elaine Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment.

Since 2016, Dr. Mardis has served as Co-Executive Director of the Institute of Genomic Medicine at Nationwide Children’s Hospital and holds the Steve and Cindy Rasmussen Endowed Chair in Genomic Medicine. She is also Professor of Pediatrics at The Ohio State University College of Medicine. Additionally, Dr. Mardis serves on the Supervisory Board, Science and Technology Committee, and the Compensation and Human Resources Committee at Qiagen.

Dr. Mardis received her Bachelor of Science degree in zoology and her Ph.D. in chemistry and biochemistry, both from the University of Oklahoma. She has authored more than 380 articles in peer-reviewed journals, has contributed chapters for several medical textbooks, and is an elected member of the U.S. National Academy of Medicine.

Elaine Mardis

Jason Ryan

Jason has served in executive leadership roles across diagnostics and therapeutics companies, with broad experience in scaling businesses from early stage to product launch and ultimately global commercialization.

Jason served as COO and CFO of Magenta Therapeutics (Nasdaq: MGTA), a company focused on developing cutting-edge therapeutics for patients with autoimmune diseases and blood cancers. Prior to that, Jason served as the CFO of Foundation Medicine, a transformative company in oncology molecular profiling. He helped lead that business through early development, its initial public offering, subsequent growth into a global commercial organization and ultimately its acquisition by Roche Holdings (Nasdaq: RHHBY). Prior to Foundation Medicine, Jason led the finance and strategic planning efforts of several other high growth life science companies.

Jason previously served on the board of directors of ArcherDX, Inc. (acquired by Invitae Corporation (NYSE: NVTA)). He began his career at Deloitte & Touche where he earned a CPA, and he received a BA in Economics from Bates College and an MBA from Babson College.

Jason Ryan

Kim Kamdar

Dr. Kamdar is a Managing Partner at Domain Associates, a venture capital fund focused on healthcare company creation. Kim has been involved in cutting-edge therapeutic and diagnostics start-ups.

Kim was founding CEO for Truvian Sciences where she remains Chair. Kim was involved with Ariosa Diagnostics until the company was acquired by Roche, Corthera until the company was sold to Novartis and BiPar Sciences until that company was sold to Sanofi. Kim was an early investor and helped to create a number of other companies including Aspen Neuroscience, Syndax Pharmaceuticals (NASDAQ: SNDX) and Adastra. Additional BOD memberships include: Alume Biosciences, EPIC Sciences, Evofem Biosciences (NASDAQ: EVFM), Obalon (NASDAQ: OBLN), Sera Prognostics and Singular Genomics.

Prior to Domain, Kim was a Kauffman Fellow at MPM Capital. She was also a Research Director at Novartis, where she built and led a team focused on the biology, genetics and genomics of model organisms. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.

Kim is currently an Advisory Board Member for Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine. Kim also serves as a BOD member for Access Youth Academy, a non-profit helping to transform the lives of underserved youth through academic enrichment, health and wellness, social responsibility and leadership through squash.

Kim Kamdar

David Barker

Dr. David L. Barker currently serves on the Boards of Directors of AmideBio, Singular Genomics Systems, and Aspen Neuroscience, and is Board Member and Chairman at Bionano Genomics (NASDAC: BNGO). He is a scientific advisor to Luna DNA. He was Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 to 2007, and on the Illumina scientific advisory board through 2015. He was previously on the Boards of NextBio, which was acquired by Illumina in 2013, ProteinSimple, which was acquired by Bio-Techne in 2014, Zephyrus Biosciences, Inc., acquired by Bio-Techne in 2016, IntegenX, acquired by Thermo Fisher Scientific in 2018, and Integrated Diagnostics, acquired by Biodesix in 2018.

Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.

In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

David-Barker-Headshot-2

Mike Pellini

Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Previously, he served as CEO and Chairman of Foundation Medicine, a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to chairman through the close of Roche’s (NASDAQ:RHHBY) acquisition of FMI in August 2018. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010.

He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Thrive Earlier Detection, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.

Mike received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.

Mike Pellini

Vincent Brancaccio

Vincent directs the Human Resources efforts with a focus on people and culture initiatives. Vincent is an experienced leader, holding a variety of HR and Finance roles at Life Technologies and Thermo Fisher Scientific. Most recently, Vincent was the Director of Global Compensation at NuVasive where he led efforts on compensation structures and incentive design. Vincent currently serves as an advisor to PeopleTech Partners, a venture capital firm focused on the human resources technology space.

Vincent received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Business Management & Economics from University of California, Santa Cruz, and currently holds an active SPHR® certification from the HRCI®.

Vincent Brancaccio

Dalen Meeter

Dalen Meeter oversees all aspects of financial operations at Singular Genomics. He brings more than 20 years of finance and accounting experience with public and private companies in the life science and technology industries. Dalen joined the company after more than 9 years at Illumina, where he held a variety of roles, most recently as Senior Director, Finance, leading the financial planning and analysis functions for the company’s Operations, Manufacturing, and R&D activities. Prior to Illumina, Dalen held various finance and accounting leadership positions at Websense (acquired by Vista Equity Partners), Captiva Software (acquired by Dell EMC), and KPMG.

Dalen earned an MBA from the Marshall School of Business at the University of Southern California, a BA in Economics from the University of California, Santa Barbara, and is a licensed CPA in the state of California.

Dalen Meeter

Daralyn Durie

Daralyn is General Counsel of Singular Genomics, where she leads the legal team. Daralyn is a founding partner of Durie Tangri LLP and has litigated and advised clients on intellectual property issues for 30 years. Daralyn is a fellow in the American College of Trial Lawyers, a past President of the Northern California Association of Business Trial Lawyers, a former co-chair of the Lawyer Representatives to the Ninth Circuit Judicial Conference, and was named by California Lawyer magazine as one of its Attorneys of the Year in 2015.

Daralyn received a JD from the University of California, Berkeley, School of Law, an MA in Comparative Literature from the University of California, Berkeley, and ABs in Human Biology and Comparative Literature from Stanford University.

Daralyn Durie

Jorge Velarde

Jorge joined Singular Genomics and established the commercial organization, serving as Senior Vice President of Corporate Development and Strategy. Jorge has helped build several highly successful organizations, from startup to public company, in the fields of genomics and clinical diagnostics. Jorge was an early business lead at Illumina as Vice President, leading corporate and business development along with alliance management functions for more than 10 years. He was one of the early employees at Gen-Probe and played a key business development role in the commercialization of DNA probe diagnostics for blood banks and clinical laboratories globally. Jorge was the scientific co-founder of Chugai Biopharmaceuticals and the co-inventor of an HIV drug that went into human clinical trials. Jorge most recently served as CEO of BaseHealth and currently serves on the board of Kura Biotech, a leading toxicology and diagnostics company.

Jorge received an MBA from the Paul Merage School of Business at the University of California, Irvine and a BS in Molecular Biology from Loyola University.

Jorge_Velarde_Web

Dave Daly

Dave joins Singular Genomics with more than 25 years of executive leadership in prominent scientific companies, including startups and large-scale commercial organizations. Dave was most recently the CEO at Thrive where he grew the business and oversaw a $2.15 billion acquisition in January 2021. Prior to Thrive, he was at Illumina as the senior vice president and general manager of commercial operations for the Americas region. In this capacity, he played a key role in the company’s long-range planning process and helped to accelerate adoption of the company’s flagship NovaSeq sequencing platform. Previously, Dave was general manager and chief commercial officer at Foundation Medicine, where he was responsible for all commercial functions, including sales, marketing, client services, payer relations, and medical affairs. Dave also led the oncology business unit at Life Technologies, served as chief commercial officer at Clarient, and worked with other health care firms like Roche Diagnostics and Abbott Laboratories.

Dave received an MA in Economics from the University of California, Santa Barbara and a BA in Economics from the University of California, Irvine.

Dave Daly

Eli Glezer

Eli founded Singular Genomics in 2016 and serves as the Chief Scientific Officer, leading both Science and Engineering R&D. Eli is passionate about advancing medicine through scientific discovery and engineering innovation. He has a broad range of expertise in physics, biology and engineering. Eli’s experience includes over 20 years of building and leading multi-disciplinary R&D teams in the biotech field. Prior to Singular Genomics, Eli served as the CTO at Meso Scale Diagnostics where he led the design and development of a market-leading multiplexed immunoassay technology, from early concepts to successful products. These instruments and assays are used for analyzing protein biomarkers in thousands of laboratories ranging from basic research to translational medicine, and have been used in over 1,500 publications. Eli’s an actively engaged technical leader and an inventor with over 60 issued US patents.

Eli received a Ph.D. in Applied Physics from Harvard University and BAs in Physics and Mechanical Engineering from the University of California, Berkeley.

Eli Glezer

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Drew Spaventa

Max Reads Application Note